Dr Richard Ho Joins Rosa & Co’s PhysioPD Modeling and Simulation Team
Cupertino, California
November 1, 2007
Rosa & Co, a leader in drug development modeling and simulation, today announced that Richard Ho, MD-PhD, has joined Rosa as a Principal.
“I am very excited to have Richard join the Rosa team,” said Sam Holtzman, PhD, Chairman, President, and CEO of Rosa & Co. “Richard has unequaled world-class experience and an enviable track record in the development and use of physiological modeling and simulation in pharmaceutical development. His experience and talent will greatly enhance our team and will accelerate our company’s growth,” Dr Holtzman added, “Richard’s joining Rosa underscores our commitment to decision-focused PhysioPD modeling and simulation.”
“I am excited to be joining the Rosa team. I have been extremely impressed with their knowledge and extensive expertise in modeling and simulation for drug discovery and development as well as health care strategy. Rosa’s portfolio of physiologic, PK/PD, and dynamic market modeling to support specific client decisions fits well with my background and research interests. I also believe that their business practice of developing custom, decision-focused simulation models that are owned by their clients yields tremendous value.” said Dr Ho.
Dr Ho is a leader in Rosa’s physiologic modeling and simulation (M&S) practice. He has been involved in biomedical research for over 20 years with experience ranging from bench experimentation to clinical trials, including a focus on systems biology and M&S since 1997. Dr Ho’s modeling expertise spans such disease areas as diabetes, obesity, anemia, acid reflux, asthma, and rheumatoid arthritis. Prior to joining Rosa, he was director of the Disease Simulation team at Johnson & Johnson Pharmaceutical Research & Development in La Jolla, CA, where he led the adoption and utilization of physiologic M&S within J&J’s pharmaceutical sector. He focused on providing decision support for both small- and large-molecule R&D.
Dr Ho completed his residency in Internal Medicine and a fellowship in Rheumatology at Yale, and has an MD-PhD from SUNY Buffalo and an AB from Harvard. He holds a California medical license.
About Rosa & Co.
Rosa & Co. is a consulting company that helps clients systematically and dramatically improve development productivity through a combination of advanced predictive methods and proven organizational processes, including: Drug-Disease Modeling and Clinical Trial Simulation; Pharmaceutical Asset, Franchise, and Portfolio Strategy; and Dynamic Market Modeling. Rosa’s leadership has played a seminal role in establishing each of these areas’ intellectual foundations, and they have demonstrated their business value during many years of professional experience. Rosa’s clients develop drugs, diagnostics, and medical devices, and range in size from pre-IPO start-ups to global pharmaceutical companies. The company’s locations in Silicon Valley, San Diego, Seattle, Philadelphia, and London allow Rosa to serve clients worldwide.
Statements in this announcement that are not strictly historical are “forward looking” statements as defined in the Private Securities Litigation Reform Act of 1995. Actual events may differ materially from those projected in forward looking statements due to uncertainties in the company's operations, development efforts, and business environment.